

HUMBLE OIL & REFINING COMPANY

MIDLAND, TEXAS

May 26, 1959

Application For Dual Completion
Humble Oil & Refining Company
South Four Lakes Unit 1, Well 6
Undesignated Pennsylvanian and
Devonian Pools
Lea County, New Mexico

New Mexico Oil Conservation Commission
P. O. Box 871
Santa Fe, New Mexico

Attention: Mr. A. L. Porter, Jr.

Gentlemen:

By letter dated April 17, 1959, Humble Oil & Refining Company requested that the New Mexico Oil Conservation Commission set for Examiner Hearing an application for a dual oil-oil completion in an Undesignated Devonian Oil Pool and an Undesignated Pennsylvanian Oil Pool for Humble's South Four Lakes Unit 1, Well 6. This well is located 1980 feet from the South and 660 feet from the East lines of Section 2, Township 12 South, Range 34 East, NMPM, Lea County, New Mexico.

By Case No. 1621, Order No. R-1371, New Mexico Oil Conservation Commission approved Humble's application for an order reclassifying Four Lakes-Devonian (Oil) Pool as a gas pool. You are requested, therefore, to amend Humble's application from a dual oil-oil completion to a dual gas-oil completion in an Undesignated Devonian Gas Pool and an Undesignated Pennsylvanian Oil Pool.

Yours very truly,

Humble Oil & Refining Company

COPY ORIGINAL
SIGNED: **H. L. HENSLEY**

R. R. McCarty
Division Production Manager

WHN:ar

cc: All Offset Operators

1. Introduction

The purpose of this study is to investigate the effects of various factors on the performance of a system. The study is organized as follows: Section 2 describes the system and the factors being investigated. Section 3 presents the experimental design and the results of the experiments. Section 4 discusses the implications of the results and provides conclusions.

The system under investigation is a complex system with many components. The factors being investigated are the input variables that affect the system's performance.

The experimental design is a factorial design with two factors: Factor A and Factor B. The results of the experiments are presented in Table 1.

The implications of the results are discussed in Section 4. The conclusions are that the system's performance is significantly affected by the input variables.

The system under investigation is a complex system with many components. The factors being investigated are the input variables that affect the system's performance. The experimental design is a factorial design with two factors: Factor A and Factor B. The results of the experiments are presented in Table 1. The implications of the results are discussed in Section 4. The conclusions are that the system's performance is significantly affected by the input variables.

The system under investigation is a complex system with many components. The factors being investigated are the input variables that affect the system's performance. The experimental design is a factorial design with two factors: Factor A and Factor B. The results of the experiments are presented in Table 1. The implications of the results are discussed in Section 4. The conclusions are that the system's performance is significantly affected by the input variables.

The system under investigation is a complex system with many components. The factors being investigated are the input variables that affect the system's performance.

The experimental design is a factorial design with two factors: Factor A and Factor B. The results of the experiments are presented in Table 1.

The implications of the results are discussed in Section 4. The conclusions are that the system's performance is significantly affected by the input variables.

Table 1

Results of the experiments

HUMBLE OIL & REFINING COMPANY

MIDLAND, TEXAS

May 26, 1959

Application For Dual Completion
Humble Oil & Refining Company
South Four Lakes Unit 1, Well 6
Undesignated Pennsylvanian and
Devonian Pools
Lea County, New Mexico

New Mexico Oil Conservation Commission
P. O. Box 871
Santa Fe, New Mexico

Attention: Mr. A. L. Porter, Jr.

Gentlemen:

By letter dated April 17, 1959, Humble Oil & Refining Company requested that the New Mexico Oil Conservation Commission set for Examiner Hearing an application for a dual oil-oil completion in an Undesignated Devonian Oil Pool and an Undesignated Pennsylvanian Oil Pool for Humble's South Four Lakes Unit 1, Well 6. This well is located 1980 feet from the South and 660 feet from the East lines of Section 2, Township 12 South, Range 34 East, NMPM, Lea County, New Mexico.

By Case No. 1621, Order No. R-1371, New Mexico Oil Conservation Commission approved Humble's application for an order reclassifying Four Lakes-Devonian (Oil) Pool as a gas pool. You are requested, therefore, to amend Humble's application from a dual oil-oil completion to a dual gas-oil completion in an Undesignated Devonian Gas Pool and an Undesignated Pennsylvanian Oil Pool.

Yours very truly,

Humble Oil & Refining Company

COPY ORIGINAL
SIGNED: H. L. HENSLEY

R. R. McCarty
Division Production Manager

WHN:ar

cc: All Offset Operators

Figure 1. The effect of the concentration of the inhibitor on the rate of polymerization of α -methylstyrene in the presence of SnCl_4 at 25°C .

[illegible]

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

2. Once the problem is identified, the next step is to define the objectives and goals of the project. This helps to clarify what needs to be achieved and provides a clear direction for the team.

3. The third step is to develop a plan or strategy to address the problem. This involves breaking down the problem into smaller, manageable tasks and determining the resources needed to complete them.

4. The fourth step is to implement the plan. This involves putting the strategy into action and monitoring progress regularly to ensure that the project is on track.

5. Finally, the fifth step is to evaluate the results of the project. This involves assessing the outcomes against the objectives and goals to determine the effectiveness of the intervention.

1. The first step in the process of identifying a problem is to recognize that a problem exists. This involves gathering information about the situation and identifying the specific issue that needs to be addressed.

1990

[illegible]

1. *Pharmaceuticals* (1998) 10: 101-102.
 2. *Pharmaceuticals* (1998) 10: 103-104.
 3. *Pharmaceuticals* (1998) 10: 105-106.
 4. *Pharmaceuticals* (1998) 10: 107-108.
 5. *Pharmaceuticals* (1998) 10: 109-110.
 6. *Pharmaceuticals* (1998) 10: 111-112.
 7. *Pharmaceuticals* (1998) 10: 113-114.
 8. *Pharmaceuticals* (1998) 10: 115-116.
 9. *Pharmaceuticals* (1998) 10: 117-118.
 10. *Pharmaceuticals* (1998) 10: 119-120.
 11. *Pharmaceuticals* (1998) 10: 121-122.
 12. *Pharmaceuticals* (1998) 10: 123-124.
 13. *Pharmaceuticals* (1998) 10: 125-126.
 14. *Pharmaceuticals* (1998) 10: 127-128.
 15. *Pharmaceuticals* (1998) 10: 129-130.
 16. *Pharmaceuticals* (1998) 10: 131-132.
 17. *Pharmaceuticals* (1998) 10: 133-134.
 18. *Pharmaceuticals* (1998) 10: 135-136.
 19. *Pharmaceuticals* (1998) 10: 137-138.
 20. *Pharmaceuticals* (1998) 10: 139-140.
 21. *Pharmaceuticals* (1998) 10: 141-142.
 22. *Pharmaceuticals* (1998) 10: 143-144.
 23. *Pharmaceuticals* (1998) 10: 145-146.
 24. *Pharmaceuticals* (1998) 10: 147-148.
 25. *Pharmaceuticals* (1998) 10: 149-150.
 26. *Pharmaceuticals* (1998) 10: 151-152.
 27. *Pharmaceuticals* (1998) 10: 153-154.
 28. *Pharmaceuticals* (1998) 10: 155-156.
 29. *Pharmaceuticals* (1998) 10: 157-158.
 30. *Pharmaceuticals* (1998) 10: 159-160.
 31. *Pharmaceuticals* (1998) 10: 161-162.
 32. *Pharmaceuticals* (1998) 10: 163-164.
 33. *Pharmaceuticals* (1998) 10: 165-166.
 34. *Pharmaceuticals* (1998) 10: 167-168.
 35. *Pharmaceuticals* (1998) 10: 169-170.
 36. *Pharmaceuticals* (1998) 10: 171-172.
 37. *Pharmaceuticals* (1998) 10: 173-174.
 38. *Pharmaceuticals* (1998) 10: 175-176.
 39. *Pharmaceuticals* (1998) 10: 177-178.
 40. *Pharmaceuticals* (1998) 10: 179-180.
 41. *Pharmaceuticals* (1998) 10: 181-182.
 42. *Pharmaceuticals* (1998) 10: 183-184.
 43. *Pharmaceuticals* (1998) 10: 185-186.
 44. *Pharmaceuticals* (1998) 10: 187-188.
 45. *Pharmaceuticals* (1998) 10: 189-190.
 46. *Pharmaceuticals* (1998) 10: 191-192.
 47. *Pharmaceuticals* (1998) 10: 193-194.
 48. *Pharmaceuticals* (1998) 10: 195-196.
 49. *Pharmaceuticals* (1998) 10: 197-198.
 50. *Pharmaceuticals* (1998) 10: 199-200.
 51. *Pharmaceuticals* (1998) 10: 201-202.
 52. *Pharmaceuticals* (1998) 10: 203-204.
 53. *Pharmaceuticals* (1998) 10: 205-206.
 54. *Pharmaceuticals* (1998) 10: 207-208.
 55. *Pharmaceuticals* (1998) 10: 209-210.
 56. *Pharmaceuticals* (1998) 10: 211-212.
 57. *Pharmaceuticals* (1998) 10: 213-214.
 58. *Pharmaceuticals* (1998) 10: 215-216.
 59. *Pharmaceuticals* (1998) 10: 217-218.
 60. *Pharmaceuticals* (1998) 10: 219-220.
 61. *Pharmaceuticals* (1998) 10: 221-222.
 62. *Pharmaceuticals* (1998) 10: 223-224.
 63. *Pharmaceuticals* (1998) 10: 225-226.
 64. *Pharmaceuticals* (1998) 10: 227-228.
 65. *Pharmaceuticals* (1998) 10: 229-230.
 66. *Pharmaceuticals* (1998) 10: 231-232.
 67. *Pharmaceuticals* (1998) 10: 233-234.
 68. *Pharmaceuticals* (1998) 10: 235-236.
 69. *Pharmaceuticals* (1998) 10: 237-238.
 70. *Pharmaceuticals* (1998) 10: 239-240.
 71. *Pharmaceuticals* (1998) 10: 241-242.
 72. *Pharmaceuticals* (1998) 10: 243-244.
 73. *Pharmaceuticals* (1998) 10: 245-246.
 74. *Pharmaceuticals* (1998) 10: 247-248.
 75. *Pharmaceuticals* (1998) 10: 249-250.
 76. *Pharmaceuticals* (1998) 10: 251-252.
 77. *Pharmaceuticals* (1998) 10: 253-254.
 78. *Pharmaceuticals* (1998) 10: 255-256.
 79. *Pharmaceuticals* (1998) 10: 257-258.
 80. *Pharmaceuticals* (1998) 10: 259-260.
 81. *Pharmaceuticals* (1998) 10: 261-262.
 82. *Pharmaceuticals* (1998) 10: 263-264.
 83. *Pharmaceuticals* (1998) 10: 265-266.
 84. *Pharmaceuticals* (1998) 10: 267-268.
 85. *Pharmaceuticals* (1998) 10: 269-270.
 86. *Pharmaceuticals* (1998) 10: 271-272.
 87. *Pharmaceuticals* (1998) 10: 273-274.
 88. *Pharmaceuticals* (1998) 10: 275-276.
 89. *Pharmaceuticals* (1998) 10: 277-278.
 90. *Pharmaceuticals* (1998) 10: 279-280.
 91. *Pharmaceuticals* (1998) 10: 281-282.
 92. *Pharmaceuticals* (1998) 10: 283-284.
 93. *Pharmaceuticals* (1998) 10: 285-286.
 94. *Pharmaceuticals* (1998) 10: 287-288.
 95. *Pharmaceuticals* (1998) 10: 289-290.
 96. *Pharmaceuticals* (1998) 10: 291-292.
 97. *Pharmaceuticals* (1998) 10: 293-294.
 98. *Pharmaceuticals* (1998) 10: 295-296.
 99. *Pharmaceuticals* (1998) 10: 297-298.
 100. *Pharmaceuticals* (1998) 10: 299-300.
 101. *Pharmaceuticals* (1998) 10: 301-302.
 102. *Pharmaceuticals* (1998) 10: 303-304.
 103. *Pharmaceuticals* (1998) 10: 305-306.
 104. *Pharmaceuticals* (1998) 10: 307-308.
 105. *Pharmaceuticals* (1998) 10: 309-310.
 106. *Pharmaceuticals* (1998) 10: 311-312.
 107. *Pharmaceuticals* (1998) 10: 313-314.
 108. *Pharmaceuticals* (1998) 10: 315-316.
 109. *Pharmaceuticals* (1998) 10: 317-318.
 110. *Pharmaceuticals* (1998) 10: 319-320.
 111. *Pharmaceuticals* (1998

100

[illegible]